SCHEMBL21484801

SCHEMBL21484801

N#C/C(=C\c1ccc(O)c(O)c1)C(=O)Nc1nc(-c2ccc(OC(F)(F)F)cc2)c(C2CCCCC2)s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 10/20 0.50
ERBB2 P04626 6/20 0.50
MRE11 P49959 1/20 0.48
DNM1 Q05193 1/20 0.47
CSNK2A1 P68400 7/20 0.44
CSNK2A2 P19784 1/20 0.44
CSNK2B P67870 1/20 0.44
CSNK2A3 Q8NEV1 1/20 0.44
SRPK1 Q96SB4 1/20 0.44
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
PSMD14 O00487 1/20 0.42
RGS12 O14924 1/20 0.42
GMNN O75496 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21484637 0.88 MRE11 (0.60) EGFRERBB2MRE11DNM1CSNK2A1
SCHEMBL21484758 0.80 EGFR (0.52) EGFRERBB2MRE11DNM1CSNK2A1
SCHEMBL21484750 0.79 MRE11 (0.60) EGFRERBB2MRE11DNM1CSNK2A1
SCHEMBL21484865 0.77 MRE11 (0.46) MRE11KDM4EALDH1A1LMNAMAPT
SCHEMBL21484606 0.73 MRE11 (0.60) EGFRERBB2MRE11DNM1CSNK2A1
SCHEMBL21484794 0.72 ERBB2 (0.50) EGFRERBB2MRE11DNM1CSNK2A1
SCHEMBL21484807 0.72 EGFR (0.61) EGFRERBB2DNM1CSNK2A1KDM4E
SCHEMBL21484896 0.71 EGFR (0.60) EGFRERBB2DNM1CSNK2A1KDM4E
SCHEMBL21484768 0.71 EGFR (0.60) EGFRERBB2DNM1CSNK2A1KDM4E
SCHEMBL21484852 0.71 EGFR (0.60) EGFRERBB2DNM1CSNK2A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
EP-3556755-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed
EP-3556755-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 EGFR 1661/4885ERBB2 2095/4885MRE11 68/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 EGFR 1661/4885ERBB2 2095/4885MRE11 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.